北京市中伦律师事务所 关于康龙化成（北京）新药技术股份有限公司 2021 年 A 股限制性股票激励计划授予价格调整、第四 个归属期归属条件成就但股票暂不上市 及部分限制性股票作废事项的 法律意见书 二〇二五年八月 北京 • 上海 • 深圳 • 广州 • 武汉 • 成都 • 重庆 • 青岛 • 杭州 • 南京 • 海口 • 东京 • 香港 • 伦敦 • 纽约 • 洛杉矶 • 旧金山 • 阿拉木图 Beijing • Shanghai • Shenzhen • Guangzhou • Wuhan • Chengdu • Chongqing • Qingdao • Hangzhou • Nanjing • Haikou • Tokyo • Hong Kong • London • New York • Los Angeles • San Francisco • Almaty | 五、结论意见 8 | | --- | 北京市中伦律师事务所 关于康龙化成（北京）新药技术股份有限公司 2021 年 A 股限制性股票激励计划授予价格调整、 第四个归属期归属条件成就但股票暂不上市 及部分限制性股票作废事项的 法律意见书 致： ...

上海妙道企业管理咨询有限公司 关于 康龙化成（北京）新药技术股份有限公司 2022 年 A 股限制性股票激励计划 第三个归属期归属条件成就相关事项 之 独立财务顾问报告 独立财务顾问： 二〇二五年八月 上海妙道企业管理咨询有限公司 独立财务顾问报告 目 录 | | 3 | 第一章 | 声 | 明 | | --- | --- | --- | --- | --- | | | 5 | 第二章 | 释 | 义 | | 第三章 | 基本假设 | | 7 | | | 第四章 | 本激励计划履行的审批程序 | | 8 | | | 第五章 | 本激励计划第三个归属期归属条件成就情况 | | 10 | | | 一、董事会就本次激励计划设定的限制性股票归属条件是否成就的审议情况 | 10 | | | | | 二、第三个归属期情况 | 10 | | | | | 三、第三个归属期归属条件成就的说明 | 10 | | | | | 11 | 四、本次实施的激励计划与已披露的激励计划相关情况的差异 | | | | | | 13 | 第六章 | 本次限制性股票可归属的具体情况 | | | 一、本次可归属的激励对象及归属数量 | 13 | | ...

康龙化成（北京）新药技术股份有限公司 2025 年半年度报告全文 康龙化成（北京）新药技术股份有限公司 Pharmaron Beijing Co., Ltd. （北京市北京经济技术开发区泰河路 6 号 1 幢八层） 2025 年半年度报告 公告编号：2025-048 2025 年 08 月 1 康龙化成（北京）新药技术股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人 Boliang Lou、主管会计工作负责人李承宗及会计机构负责人 （会计主管人员）李承宗声明：保证本半年度报告中财务报告的真实、准确、 完整。 所有董事均已出席了审议本次半年报的董事会会议。 报告中涉及的未来发展计划等前瞻性陈述属于计划性事项，不构成公司 对投资者的实质性承诺，投资者及相关人士均应对此保持足够的风险认识， 并且应当理解计划、预测与承诺之间的差异，敬请投资者注意投资风险。 公司在本报告"第三节 管理层讨论与分析"中"十、公司面临的风险和应对 措施 ...

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 海外監管公告 本公告乃康龍化成（北京）新藥技術股份有限公司（「本公司」）根據香港聯合交易所 有限公司證券上市規則第13.10B條作出。 茲載列本公司於深圳證券交易所網站刊登公告如下，僅供參閱。 承董事會命 康龍化成（北京）新藥技術股份有限公司 主席 樓柏良博士 中華人民共和國，北京 2025年8月21日 於本公告日期，董事會包括執行董事樓柏良博士、樓小強先生及鄭北女士；非執 行董事李家慶先生及萬璇女士；獨立非執行董事李麗華女士、曾坤鴻先生及余堅 先生。 证券代码：300759 证券简称：康龙化成 公告编号：2025-041 康龙化成（北京）新药技术股份有限公司 第 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 截至2025年6月30日止六個月中期業績公告 財務摘要及要點 | | 截至6月30日止六個月 | | | | --- | --- | --- | --- | | | 2025年 | 2024年 | 變動 | | | 人民幣千元 | 人民幣千元 | % | | 收益 | 6,440,951 | 5,604,463 | 14.9 | | 毛利 | 2,172,201 | 1,848,051 | 17.5 | | 母公司擁有人應佔利潤 | 701,396 | 1,113,403 | (37.0) | | 母公司擁有人應佔非國際財務報告 | | | | | 準則經調整淨利潤 | 755,701 | 690,266 | 9.5 ...

Core Insights - The healthcare services sector experienced a rise of 1.26% on August 18, with a net outflow of 1.405 billion yuan in principal funds [1] - Among the constituent stocks, 33 increased in value while 9 decreased [1] Fund Flow Analysis - The top net outflows were recorded for WuXi AppTec at 478 million yuan, Innovent Biologics at 410 million yuan, and Kelun Pharmaceutical at 175 million yuan [1] - Other notable outflows included Sanbo Brain Science at 157 million yuan and Ruizhi Pharmaceutical at 54.73 million yuan [1] Stock Performance - Key stocks with significant performance included: - Kanglong Chemical with a price of 30.94 and an increase of 2.35%, attracting a net inflow of 68.68 million yuan [1] - Baihua Pharmaceutical at 8.78, up 10.03%, with a net inflow of 63.97 million yuan [1] - Aier Eye Hospital at 13.22, up 1.34%, with a net inflow of 784.89 thousand yuan [1] - Huakang Clean at 33.28, up 13.39%, with a net inflow of 3316.13 thousand yuan [1] - Tongce Medical at 46.18, up 2.26%, with a net inflow of 3071.04 thousand yuan [1]

Core Viewpoint - The article discusses the performance of the Shanghai Composite Index and the Hang Seng Index on August 14, highlighting the stock price movements of Kanglong Chemical, a key player in the life sciences industry, and its A/H share premium status [1]. Group 1: Market Performance - On August 14, the Shanghai Composite Index fell by 0.46%, closing at 3666.44 points, while the Hang Seng Index decreased by 0.37%, closing at 25519.32 points [1]. Group 2: Company Overview - Kanglong Chemical (stock code: 300759.SZ/3759.HK) is a major service provider in the life sciences sector, established in 2004. The company has invested in talent and facilities, developing extensive research, development, and production capabilities across drug discovery, preclinical, and clinical development [1]. - The company offers a range of therapeutic approaches, including small molecules, biologics, and CGT products, and has a strong track record in providing R&D solutions for partners in North America, Europe, Japan, and China [1]. Group 3: A/H Share Premium - Kanglong Chemical's A/H share premium reached 46.69%, ranking it 74th among A/H shares. As of the close, the A-share price was 30.17 yuan, down by 2.17%, while the H-share price was 22.5 Hong Kong dollars, up by 1.26% [1].

Market Performance - On August 13, the medical services sector rose by 4.02%, led by Innovative Medical [1] - The Shanghai Composite Index closed at 3683.46, up 0.48%, while the Shenzhen Component Index closed at 11551.36, up 1.76% [1] Individual Stock Performance - The table lists various stocks in the medical services sector, with notable declines including *ST Bio down 4.95% and ST Zhongzhu down 2.66% [1] - Other stocks such as Lanwei Medical and Baicheng Pharmaceutical also experienced minor declines of 1.76% and 1.59% respectively [1] Capital Flow Analysis - The medical services sector saw a net inflow of 1.962 billion yuan from institutional investors, while retail investors experienced a net outflow of 1.888 billion yuan [3] - Notable stocks with significant net inflows from institutional investors include Yaoming Kande with 1.13 billion yuan and Kanglong Huacheng with 248 million yuan [3] - Conversely, retail investors showed significant outflows from stocks like Yaoming Kande and Kanglong Huacheng, indicating a shift in investor sentiment [3]

Group 1 - CRO concept stocks have shown significant gains, with notable increases in share prices for companies such as Viatris (up 12.83% to HKD 2.11), Zhaoyan New Drug (up 9.23% to HKD 24.62), and others [1] - WuXi AppTec has raised its full-year sales forecast after reporting a 141.6% year-on-year increase in TIDES business revenue, reaching RMB 5.03 billion in the first half of the year, driven by high demand in the GLP-1 sector [1] - CICC believes that the valuation center for innovative drug sectors has been adjusted upwards, which will enhance domestic new drug R&D demand and increase financing activity for primary innovative drug projects [1] Group 2 - The U.S. Bureau of Labor Statistics reported stable inflation in July, reducing barriers for potential interest rate cuts by the Federal Reserve in September, indicating a recovery trend in overall investment and financing [2] - The domestic market for preclinical CRO, clinical CRO, and CDMO services has stabilized in pricing, with a steady recovery in new orders expected to lead to an industry turnaround [2] - Internationally, the CDMO pricing system remains reasonable, and the impact of high pandemic baselines has been absorbed, suggesting a positive trend for overseas orders [2]

Group 1 - The core viewpoint is that the expectation of a Federal Reserve interest rate cut is boosting sentiment in the pharmaceutical sector, with the Medical Innovation ETF (516820.SH) rising by 1.04% [1] - Key stocks such as Haisco (002653), Baili Tianheng (688506), and Kanghong Pharmaceutical (002773) saw significant increases of 4.86%, 3.97%, and 3.91% respectively [1] - The U.S. July core CPI rose by 0.3%, slightly exceeding expectations, while inflation for tariff-sensitive goods remained moderate, reinforcing the expectation of a 25 basis point rate cut in September [1] Group 2 - Longjiang Securities noted that despite the typical vacation period for overseas pharmaceutical executives in July and August, there has been a notable acceleration in overseas expansion, with Chinese innovative drugs reaching $30 billion in exports in just one and a half months [2] - The acceleration in overseas expansion is attributed to pressures in the overseas industry and an increase in the "new" content of domestic innovative drugs [2] - The expectation of a weaker U.S. economy and employment data is likely to accelerate the pace of Federal Reserve rate cuts, enhancing global liquidity and benefiting technology stocks, which may provide an opportunity for investors to capitalize on the rebound in core pharmaceutical assets through the Medical Innovation ETF (516820) [2]